Quiet today — no notable KOL discussion in the last 48 hours.
An analysis of the RxPONDER trial for HR-positive, HER2-negative early breast cancer showed that baseline anti-Müllerian hormone (AMH) levels refine chemotherapy selection. Among premenopausal patients with a recurrence score ≤25, those with low AMH levels did not benefit from chemotherapy, and AMH outperformed age and menopausal status in predicting this benefit.
“Baseline AMH outperformed age and menopausal status in predicting chemotherapy benefit among premenopausal patients with HR+/ HER2-, RS ≤25 disease.”
— @Dr_Oncologista · RxPONDER / AMH · View post ↗
“In RxPONDER, among premenopausal patients aged<55, those with low AMH levels did not benefit from chemotherapy”
— @Annals_Oncology · RxPONDER / AMH · View post ↗
“breast cancer is rising among adolescent & young adult (AYA) women — ages 15–39 — across Southeast Asia.”
— @TheCORGILab · AYA Epidemiology · View post ↗The 5-year STELLAR update for locally advanced rectal cancer (LARC) showed that total neoadjuvant therapy (TNT) with preoperative CAPOX did not improve distant metastasis, DFS, or local recurrence rates, though a borderline OS benefit was observed. Additionally, the full publication of the COMMIT trial in MSI-H CRC demonstrated that FFX/bevacizumab/atezolizumab was superior to atezolizumab monotherapy, prompting discussion on using induction chemotherapy with IO to reduce early progression.
“Despite moving 4 cycles of CAPOX preop, DM, DFS, and LRR were all very similar between the two groups.”
— @kahvecioglu_a · STELLAR trial in LARC · View post ↗“the optimal sequence of chemo and RT, as well as the choice between short course and long course CRT is still not fully settled.”
— @kahvecioglu_a · Total Neoadjuvant Therapy (TNT) for LARC · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
In the Phase 1 #RTIRE trial, focal irreversible electroporation (IRE) plus reduced-dose radiation for intermediate-risk prostate cancer yielded negative biopsies at 12 months for all 10 patients with no grade 3–5 adverse events; the investigator noted the results are 'Promising, NOT definitive.' Separately, pathological complete response rates of 57–64% with perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer (MIBC) are prompting discussion on whether cystectomy can be spared in select patients.
“With pCR rates of 57–64% with perioperative EV + pembrolizumab in MIBC, can cystectomy be spared in selected patients who achieve a complete response?”
— @drenriquegrande · MIBC cystectomy-sparing · View post ↗
“Phase 1 #RTIRE: focal IRE + reduced-dose RT (32.5 Gy/5 fx) for intermediate risk prostate cancer: ✅ 10/10 negative biopsies at 12 mo ✅ No grade 3–5 AEs”
— @HimanshuNagarMD · #RTIRE trial results · View post ↗
“Should very low-risk prostate cancer on active surveillance be considered a contraindication to anatomical enucleation?”
— @RomanCarvajal · Active surveillance and BPH surgery · View post ↗Upcoming ECOG-ACRIN trials will evaluate novel combinations in multiple myeloma, including the Phase Ib/II EAA242 study of teclistamab/pomalidomide versus carfilzomib/pomalidomide/dexamethasone in early relapse. Other planned studies include PrE1005, comparing belantamab mafodotin with VRd to daratumumab with VRd in newly diagnosed patients, and the Phase II EAA241 trial for newly diagnosed myeloma with light chain cast nephropathy. Separately, a descriptive pooled analysis in Blood Advances reviewed the efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis.
“Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis”
— @HadidiSamer · BCMA in AL Amyloidosis · View post ↗📌 Amplified by @KolPulseAI
“#EAonc EAA242 - Phase Ib/II Fixed Duration Study of Teclistamab/Pomalidomide (TP) vs Carfilzomib/Pomalidomide/Dex (KPd) in Early Relapse of Multiple Myeloma”
— @mtmdphd · EAA242 Trial Design · View post ↗“PrE1005 - Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone [Bel-VRd vs DVRd) for Newly Diagnosed Multiple Myeloma [NDMM]”
— @mtmdphd · PrE1005 Trial Design · View post ↗“EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN)”
— @mtmdphd · EAA241 Trial Design · View post ↗Data from the STARGLO and POLARGO trials in transplant-ineligible R/R DLBCL show nearly identical overall survival hazard ratios (0.59 and 0.60, respectively) versus R-GemOx, prompting discussion on the need to compare trials beyond a single endpoint. Primary results from the TRANSCEND CLL 004 trial for lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL were also shared. Additionally, the European Society for Blood and Marrow Transplantation (EBMT) published new practice recommendations for cellular therapy in mantle cell lymphoma.
“Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004”
— @DrRaulCordoba · TRANSCEND CLL 004 · View post ↗“Cellular therapy in mantle cell #lymphoma: recommendations from the @TheEBMT practice harmonisation and guidelines committee”
— @DrRaulCordoba · MCL Cellular Therapy Guidelines · View post ↗
“Do not compare hazard ratios alone. Compare the patients, Kaplan-Meier curves, absolute outcomes, durability, and safety.”
— @HenrychihangFu1 · DLBCL Trial Interpretation · View post ↗